Multiple Sclerosis Clinical Trial

Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)

Summary

The main objectives of Part 1 are as follows: To evaluate the safety, tolerability, and efficacy of BG00012 in pediatric subjects with RRMS, as compared with a disease-modifying treatment and to assess health outcomes and evolution of disability. The primary objective of Part 2 is to evaluate the long-term safety of BG00012 in subjects who completed Week 96 in Part 1 of Study 109MS306. The secondary objective of Part 2 is to describe the long-term MS outcomes of BG00012 in subjects who completed Week 96 in Part 1 of Study 109MS306.

View Eligibility Criteria

Eligibility Criteria

Key Inclusion Criteria:

Must have a body weight of ≥30 kg.
Must have a diagnosis of RRMS (consensus definition for pediatric RRMS [Krupp 2007]).
Must be ambulatory with a baseline EDSS score between 0 and 5.5, inclusive.
Must have experienced at least 1 of the following 3 conditions: a) at least 1 relapse within the last 12 months prior to Day 1 with a prior brain MRI demonstrating lesions consistent with MS; b) at least 2 relapses within the last 24 months prior to Day 1, with a prior brain MRI demonstrating lesions consistent with MS; c) evidence of Gd-enhancing lesions of the brain on an MRI performed within the 6 weeks prior to Day 1.
Must be neurologically stable, with no evidence of relapse within 50 days prior to Day 1 and no evidence of corticosteroid treatment within 30 days prior to Day 1.
Subjects of childbearing potential who are sexually active must be willing to practice effective contraception during the study and be willing and able to continue contraception for at least 30 days after their final dose of study treatment.

Key Exclusion Criteria:

Primary progressive, secondary progressive, or progressive relapsing MS (as defined by [Lublin and Reingold 1996]). These conditions require the presence of continuous clinical disease worsening over a period of at least 3 months. Subjects with these conditions may also have superimposed relapses but are distinguished from relapsing-remitting subjects by the lack of clinically stable periods or clinical improvement.
Disorders mimicking MS, such as other demyelinating disorders (e.g., acute disseminated encephalomyelitis), systemic autoimmune disorders (e.g., Sjögren disease, lupus erythematosus), metabolic disorders (e.g., dystrophies), and infectious disorders.
History of premalignant or malignant disease. Subjects with basal cell carcinoma that has been completely excised prior to screening will remain eligible.
History of severe allergic or anaphylactic reactions, or known drug hypersensitivity to DMF, fumaric acid esters, or interferon beta-1a (IFN Beta-1a).
History of abnormal laboratory results indicative of any significant endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, renal, and/or any other major disease that would preclude participation in a clinical study.

History of clinically significant cardiovascular, pulmonary, GI, dermatologic, growth, developmental, psychiatric (including depression), neurologic (other than MS), and/or other major disease that would preclude participation in a clinical study.

-.History of human immunodeficiency virus.

An MS relapse that has occurred within 50 days prior to Day 1 AND/OR the subject has not stabilized from a previous relapse prior to Day 1.
Other unspecified reasons that, in the opinion of the Investigator or Biogen Idec, make the subject unsuitable for enrollment.
For the PD/PK subset of subjects: subjects unable to swallow the BG00012 capsule whole.

Key Treatment history

Any previous treatment with Fumaderm (fumaric acid esters) or BG00012.
Prior treatment with any of the following: total lymphoid irradiation, cladribine, T-cell or T-cell receptor vaccination, any therapeutic monoclonal antibody, with the exception of rituximab or natalizumab.
Prior treatment with any of the following medications within the 12 months prior to Day 1: mitoxantrone, cyclophosphamide, rituximab.
Prior treatment with any of the following medications or procedures within 6 months prior to Day 1: fingolimod; teriflunomide; natalizumab; cyclosporine; azathioprine; methotrexate; mycophenolate mofetil; laquinimod; intravenous (IV) immunoglobulin; plasmapheresis or cytapheresis
Treatment with any of the following medications within 30 days prior to Day 1: steroids (IV or oral corticosteroid treatment, including agents that may not act through the corticosteroid pathway [e.g.low dose naltrexone]), 4-aminopyridine or related products (except subjects on a stable dose of controlled-release fampridine for 3 months)

NOTE: Other protocol-defined inclusion/exclusion criteria may apply

Study is for people with:

Multiple Sclerosis

Phase:

Phase 3

Estimated Enrollment:

156

Study ID:

NCT02283853

Recruitment Status:

Active, not recruiting

Sponsor:

Biogen

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 61 Locations for this study

See Locations Near You

Research Site
Boston Massachusetts, 02115, United States
Research Site
Charlottesville Virginia, 22903, United States
Research Site
Brussels , 1020, Belgium
Research Site
Gent , 9000, Belgium
Research Site
Sofia , 1113, Bulgaria
Research Site
Calgary , T3B 6, Canada
Research Site
Brno , 656 9, Czechia
Research Site
Hradec Kralove , 500 0, Czechia
Research Site
Jihlava , 58633, Czechia
Research Site
Ostrava - Poruba , 708 5, Czechia
Research Site
København , 2100, Denmark
Research Site
Odense , 5000, Denmark
Research Site
Århus C , 8000, Denmark
Research Site
Strasbourg Bas Rhin, 67098, France
Research Site
Dijon Cedex Cote dÝOr, 21033, France
Research Site
Rennes cedex 09 Ille Et Vilaine, 35033, France
Research Site
Bron Cedex Rhone, 69677, France
Research Site
Amiens Cedex 1 Somme, 80054, France
Research Site
Vandoeuvre les Nancy Vandoeuvre Les Nancy Cedex, 54511, France
Research Site
Clermont Ferrand , 63003, France
Research Site
Le Kremlin Bicêtre , 94275, France
Research Site
Lille Cedex , 59037, France
Research Site
Marseille , 13385, France
Research Site
Montpellier , 34295, France
Research Site
Augsburg Bayern, 86156, Germany
Researh Site
Bochum , 44791, Germany
Research Site
Muenchen , 80337, Germany
Research Site
Budapest , 1083, Hungary
Research Site
Budapest , 1089, Hungary
Research Site
Jerusalem , 91120, Israel
Research Site
Petach-Tikva , 49202, Israel
Resaerch Site
Ramat-Gan , 52621, Israel
Research Site
Gallarate Varese, 21013, Italy
Research Site
Bari , 70124, Italy
Research Site
Genova , 16132, Italy
Research Site
Milano , 20132, Italy
Research Site
Napoli , 80131, Italy
Research Site
Padova , 35128, Italy
Research Site
Palermo , 90127, Italy
Research Site
Rome , 00165, Italy
Research Site
Rome , 00189, Italy
Research Site
Kuwait Shuwaikh, 73767, Kuwait
Research Site
Bialystok , 15-27, Poland
Research Site
Gdansk , 80-95, Poland
Research Site
Lodz , 93-33, Poland
Research Site
Poznan , 60-35, Poland
Research Site
Warsaw , 04-73, Poland
Research Site
Belgrade , 11000, Serbia
Research Site
Belgrade , 11070, Serbia
Resaerch Site
Kragujevac , 34000, Serbia
Research Site
Barcelona , 8036, Spain
Resaeach Site
Cordoba , 14011, Spain
Research Site
Madrid , 28850, Spain
Resaerch Site
Sevilla , 41009, Spain
Research Site
Göteborg , 41345, Sweden
Research Site
Stockholm , 17176, Sweden
Research Site
Ankara , 06100, Turkey
Research Site
Antalya , 07070, Turkey
Research Site
London Greater London, SE1 7, United Kingdom
Research Site
London Greater London, WC1N , United Kingdom
Research Site
Birmingham West Midlands, B4 6N, United Kingdom
Research Site
London , WC1N , United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Multiple Sclerosis

Phase:

Phase 3

Estimated Enrollment:

156

Study ID:

NCT02283853

Recruitment Status:

Active, not recruiting

Sponsor:


Biogen

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.